Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 22;11:4788. doi: 10.1038/s41467-020-18524-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a Histological sections of 3D organotypic cultures of human keratinocytes expressing the indicated proteins (left) that have been treated with the inhibitors shown on top. Scale bar, 10 μm (n = 3 independent cultures). b Thickness of the cellular and corneum strata using data from a. *P = 0.012 (Vav2^Onc vehicle, stratum corneum), 0.037 (Rac1^F28L + RhoA^F30L vehicle, stratum corneum); ***P < 0.0001 (all other tests) (ANOVA and Dunnett’s multiple comparison test, n = 3 independent cultures). c Demonstration that the transcriptional activity of c-MYC and TEAD is inhibited by MYC (10058-F4) and YAP/TEAD interaction (Verteporfin) inhibitors, respectively. Black and gray stars indicate the P value of the indicated experimental values when compared to EGFP-transfected and vehicle-treated cells, respectively. **P = 0.003 (EGFP, 100058-F4, MYC activity), 0.002 (Vav2^Onc+E200A, 100058-F4, MYC activity), 0.001 (Vav2^Onc+E200A, vehicle, YAP/TEAD activity), 0.001 (EGFP, Verteporfin, YAP/TEAD activity), 0.002 (Vav2^Onc+E200A, Verteporfin, YAP/TEAD activity); ***, P < 0.0001 (all other tests) (ANOVA and Tukey’s HSD test, n = 3 independent experiments). d Expression of endogenous and ectopic c-Myc in indicated cell lines. Tubulin was used as loading control (bottom). n = 3 independent experiments. e Staining of indicated human keratinocytes (left) with hematoxylin-eosin (left and middle two rows of panels) and antibodies to Ki67 (two top middle panels), IVL (two right panels on top, red color), K14 (two right panels on top, green color), ectopically expressed c-Myc (left bottom panel), endogenous Cyclin D1 (middle bottom panel) and endogenous c-FOS (right bottom panel). When indicated, some sections were counterstained with DAPI (two right panels on top. blue color). Scale bar, 10 μm (n = 3 independent cultures). In b and c, data represent the mean ± SEM. Source data for this figure are provided as a Source Data file.